PEPG logo

PepGen Inc. (PEPG)

$3.88

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PEPG

Market cap

$365732893

EPS

-0.78

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.015495

Price on PEPG

Previous close

$4.19

Today's open

$4.12

Day's range

$3.62 - $4.20

52 week range

$1.31 - $7.80

Profile about PEPG

CEO

James McArthur

Employees

57

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

94261055

Issue type

Common Stock

PEPG industries and sectors

Healthcare

Biotechnology & Life Sciences

News on PEPG

PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones

PepGen is upgraded from "Hold" to "Buy" after strong 10 mg/kg phase 2 data for PGN-EDODM1 in DM1, showing 46.5% mean splicing correction. PEPG's positive data eliminates prior outlier concerns and supports a path toward an end-of-phase 2 FDA meeting in 2H 2027, with phase 3 initiation as a potential next step. Advancement to the 12.5 mg/kg cohort and upcoming FREEDOM-OLE study readouts in early 2027 provide additional catalysts and proof-of-concept opportunities.

news source

Seeking Alpha • Nov 12, 2026

news preview

PepGen Announces Pricing of $125 Million Public Offering

BOSTON--(BUSINESS WIRE)--PepGen Announces Pricing of $125.0 Million Public Offering.

news source

Business Wire • Nov 12, 2026

news preview

PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes

PepGen Inc. surged over 100% on positive Phase 2 FREEDOM2-DM1 top-line results for PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PGN-EDODM1 achieved a mean 46.5% splicing correction and notable functional improvements, with a favorable safety profile at 10 mg/kg over four doses. Despite promising data, the U.S. clinical hold persists, and the small sample size (six treated patients) warrants caution pending further results.

news source

Seeking Alpha • Nov 11, 2026

news preview

PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights.

news source

Business Wire • Nov 10, 2026

news preview

PepGen Stock Doubles in One Session - Here's Why

PepGen Inc. (NASDAQ:PEPG) stock surged on Tuesday with a strong session Volume of 31.855 million, compared to an average volume of 983.011 thousand, according to Benzinga Pro data.

news source

Benzinga • Nov 10, 2026

news preview

PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results Transcript

PepGen Inc. ( PEPG ) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results November 10, 2026 8:00 AM EST Company Participants James McArthur - President, CEO, Treasurer, Secretary & Director Paul Streck - Executive VP and Head of Research & Development Conference Call Participants Laurence Watts Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Laura Chico - Wedbush Securities Inc., Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the PepGen conference call to discuss top line results from lowest dose MAD cohort in the Phase II FREEDOM2 study, demonstrating promising safety, splicing and vHOT data.

news source

Seeking Alpha • Nov 10, 2026

news preview

PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results.

news source

Business Wire • Nov 10, 2026

news preview

PepGen Announces Proposed $125.0 Million Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)--PepGen Announces Proposed $125.0 Million Public Offering of Common Stock.

news source

Business Wire • Nov 10, 2026

news preview

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.

news source

Business Wire • Aug 6, 2026

news preview

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.

news source

Business Wire • Aug 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in PepGen Inc.

Open an M1 investment account to buy and sell PepGen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PEPG on M1